8-K: Plus Therapeutics Secures Up to $50 Million Equity Financing Facility with Lincoln Park Capital

Plus Therapeutics, Inc. has entered into a purchase agreement with Lincoln Park Capital Fund, LLC, providing the company with access to up to $50 million in capital through common stock sales over a 36-month period.

Summary

• Plus Therapeutics, Inc. (PSTV) has signed a purchase agreement and a registration rights agreement with Lincoln Park Capital Fund, LLC, allowing the company to sell up to $50 million of its common stock over a 36-month period.
• The company has the discretion to sell shares to Lincoln Park Capital, but is not obligated to do so.
• Regular purchases can be up to 300,000 shares per day (increasing to 400,000 or 500,000 shares if the closing price is above $0.50 or $0.75, respectively), with a maximum commitment of $1,000,000 per regular purchase.
• The purchase price for regular purchases will be 97% of the lower of the lowest sale price on the purchase date or the arithmetic average of the three lowest closing sale prices during the preceding 10 business days.
• Accelerated and Additional Accelerated Purchases are also permitted, with a purchase price of 96.5% of the lower of the volume weighted average price (VWAP) or the closing sale price on the purchase date.
• A floor price of $0.10 per share applies to regular purchases.
• The company will pay an initial commitment fee of $500,000 (cash, stock, or combination) between July 1, 2025, and August 8, 2025.
• An additional commitment fee of $500,000 will be paid if the company sells over $25 million of common stock under the agreement.
• Stockholder approval will be required if the aggregate number of shares issued under the agreement exceeds 10,194,593 shares (19.99% of outstanding shares prior to the agreement), unless the average price of all sales equals or exceeds $0.3576 per share.
• Proceeds from the sales are expected to be used for working capital, general corporate purposes, and a 'Make-Whole Repayment' of approximately $17.3 million to certain warrant holders from a March 4, 2025, issuance, using 90% of proceeds from any capital raised subsequent to July 1, 2025.
• Lincoln Park Capital has agreed not to engage in short selling or hedging of the company's shares, and Plus Therapeutics will not enter into other equity line of credit or at-the-market transactions with third parties.

Sentiment

Score: 7

Explanation: The agreement provides a substantial and flexible funding source for Plus Therapeutics, which is a positive for its operational continuity and strategic initiatives. While there is potential for dilution and commitment fees, securing up to $50 million in capital is a significant positive for a company in its development stage, especially with the investor's commitment against short selling. The repayment obligation is a pre-existing liability being addressed.

Positives

• Secures flexible access to up to $50 million in capital, providing significant liquidity for working capital and general corporate purposes.
• The company retains the right, but not the obligation, to sell shares, offering control over the timing and amount of capital raised.
• Lincoln Park Capital is prohibited from short selling or hedging the company's shares, which can help mitigate downward pressure on the stock price.
• The company has the right to terminate the Purchase Agreement at any time, at no cost or penalty, providing flexibility to pursue other financing options if favorable.
• The agreement includes provisions for accelerated purchases, allowing for quicker capital raises under certain market conditions.

Negatives

• Potential for significant shareholder dilution as shares are sold to Lincoln Park Capital over time.
• Shares are sold at a discount to market prices (97% for regular purchases, 96.5% for accelerated purchases), which can lead to greater dilution.
• The company is obligated to pay commitment fees totaling up to $1 million ($500,000 initial, $500,000 additional after $25M raised).
• A substantial portion of future capital raised (90% of proceeds after July 1, 2025) is earmarked for a 'Make-Whole Repayment' of approximately $17.3 million to prior warrant holders, reducing net proceeds available for other corporate uses.
• Stockholder approval is required if the number of shares issued exceeds 19.99% of outstanding shares, which could limit the amount of capital raised without a shareholder vote.
• The company is restricted from entering into other equity line of credit or at-the-market transactions, limiting alternative financing options during the agreement term.

Risks

• **Dilution Risk**: The issuance of new common stock to Lincoln Park Capital will dilute the ownership percentage of existing shareholders.
• **Market Price Volatility**: The amount of capital raised and the extent of dilution will depend on the company's stock price at the time of sales, which can be volatile.
• **Shareholder Approval Risk**: If the company needs to issue more than 10,194,593 shares (19.99% of pre-agreement outstanding shares) and the average sale price is below $0.3576, it will require stockholder approval, which may not be obtained or could cause delays.
• **Floor Price Risk**: Regular purchases are subject to a $0.10 floor price; if the stock consistently trades below this, the company's ability to raise capital through regular purchases would be limited.
• **Suspension Events**: The agreement can be suspended or terminated under various conditions, including registration statement lapses, trading suspensions, delisting, failure to issue shares, or bankruptcy proceedings, which could cut off access to funding.
• **Make-Whole Repayment Obligation**: A significant portion of future capital raises is committed to repaying prior warrant holders, potentially limiting the net funds available for strategic initiatives or operational needs.

Future Outlook

Plus Therapeutics expects to use the net proceeds from this financing facility for working capital and general corporate purposes. A significant portion of the proceeds will also be allocated to a 'Make-Whole Repayment' of approximately $17.3 million to certain warrant holders from a previous issuance. The company has the flexibility to draw on the facility over a 36-month period, allowing it to manage its capital needs based on operational requirements and market conditions.

Industry Context

This common stock purchase agreement, often referred to as an 'equity line of credit' or 'at-the-market' (ATM) facility, is a common financing tool for small-cap companies, particularly in the biotechnology and pharmaceutical sectors. It provides flexible access to capital over an extended period without the immediate dilution or upfront costs associated with a traditional public offering. Companies often utilize such facilities to fund ongoing research and development, clinical trials, or general corporate expenses, especially when their stock price is volatile or they prefer to raise capital opportunistically. The terms, including the discount to market price and the 19.99% exchange cap (a Nasdaq rule to avoid immediate shareholder approval), are standard for this type of financing.

Comparison to Industry Standards

• The structure of this agreement, allowing the company to sell shares at its discretion over time, is a common 'equity line of credit' model, similar to facilities used by numerous small-cap biotech firms like 'XBiotech Inc.' or 'OncoSec Medical Inc.' in their early-stage development.
• The discount rates (97% for regular purchases, 96.5% for accelerated) are within the typical range for such agreements, which often see discounts between 3% and 10% to ensure liquidity for the investor.
• The 19.99% 'Exchange Cap' is a standard Nasdaq requirement (Rule 5635(d)) to avoid triggering a mandatory shareholder vote for equity issuances that could result in a change of control or significant dilution, a practice observed across many listed companies.
• The commitment fees of up to $1 million are customary for securing such a facility, reflecting the investor's commitment and the flexibility provided to the company.
• The 'Make-Whole Repayment' to warrant holders is a specific liability for Plus Therapeutics, not a standard industry financing feature, but rather a consequence of a prior financing arrangement. This could be compared to how other companies manage prior debt or warrant obligations when securing new capital, though the 115% repayment is specific to this company's prior agreement.

Related Party Transactions

• The Purchase Agreement and Registration Rights Agreement are between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC. While Lincoln Park Capital is an external investor, the terms of the agreement, including commitment fees and specific purchase mechanisms, constitute a material definitive agreement that could be considered a related party transaction in the context of financing arrangements.

Stakeholder Impact

• **Shareholders**: Will experience dilution as new shares are issued, potentially impacting per-share value. However, the funding provides capital for company operations and potentially value-creating activities.
• **Company (Management/Operations)**: Gains significant financial flexibility with access to up to $50 million, enabling continued operations, R&D, and general corporate purposes. The ability to control the timing of sales is beneficial.
• **Warrant Holders (March 4, 2025)**: Will receive a 'Make-Whole Repayment' of approximately $17.3 million, providing a favorable return on their prior investment.
• **Creditors**: The repayment of warrant holders could improve the company's balance sheet by addressing a prior obligation, potentially enhancing creditworthiness.

Next Steps

• The company must file a registration statement covering the resale of shares within 10 business days from June 17, 2025.
• The SEC needs to declare the registration statement effective for sales to commence.
• The company will pay an initial commitment fee of $500,000 to Lincoln Park Capital between July 1, 2025, and August 8, 2025.
• Plus Therapeutics may, at its discretion, sell common stock to Lincoln Park Capital over the next 36 months.
• If sales exceed 19.99% of outstanding shares and the average price is below $0.3576, the company will need to seek stockholder approval.
• The company will use 90% of proceeds from capital raised after July 1, 2025, to make an approximate $17.3 million 'Make-Whole Repayment' to certain warrant holders.

Key Dates

Recommendation

Keywords

Equity Financing, Common Stock Purchase Agreement, Lincoln Park Capital, Dilution, Capital Raise, SEC Filing, 8-K, Biotechnology, Pharmaceuticals, Warrant Repayment, Nasdaq